Medifast (MED) Stock Analysis & AI Equity Report
Medifast (MED) overview
Medifast (MED) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 386m and operating profit of USD -14.2m; the year-end share price was 10.68 USD and market capitalisation was USD 117m. Medifast is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Medifast's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Medifast
Medifast is a health and wellness company offering a coach-guided system focused on weight loss and metabolic health. Its program combines individualized support from independent coaches, community, a habit-creation framework, and nutrition plans and products. The company serves individuals seeking support with weight management, healthy habits, and broader well-being through a personalized, behavior-based approach.
Generate the Medifast report
Medifast is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Medifast and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Medifast
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.